Industry Developments
Russia
The Federal Antimonopoly Service's decision, to block a proposed merger between Abbott Laboratories Petrovax Pharm, while unexpected, does not signal a worsening investment climate...
2013-04-22Ukraine
BMI View: The announcement by the health minister that compulsory health insurance is unlikely to be rolled out in the short term is disappointing but not unexpected, given the country's...
2013-04-10Ukraine
BMI View: Although largely regressive, the impact of the government's move to limit medicine procurement to domestic production will be low, given the small scale of state drug expenditure...
2013-04-09BMI View: With the exception of Kazakhstan, the Central Asian republics remain largely insular. The significant barriers to entry for multinational drugmakers and the level of state...
2013-04-08Russia
BMI View: Moves by Russia's Ministry of Industry and Trade to liberalise the over-the-counter (OTC) medicine sector are coming to fruition, with the Health Ministry having the final...
2013-04-03BMI View: Trade data from UN Comtrade highlights the challenging conditions present in 2012, as imports fell in countries affected by the eurozone decline, such as Turkey and the Czech...
2013-03-27Ukraine
BMI View: Drugmakers in Emerging Europe must contend with import restrictions as countries including Russia and Ukraine attempt to develop their own nascent pharmaceutical sectors and...
2013-03-25Russia
BMI View: While drug imports may have declined in 2012, we believe the innovation gap between multinational and Russian drugmakers will continue to favour the multinationals. Russia's...
2013-03-22
